- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Vermont, Connecticut Governors Sign Biosimilar Substitution Legislation
Vermont and Connecticut have recently signed laws providing a pathway for and regulations around the substitution of interchangeable biosimilars for the reference biologic product at the pharmacy level.
A number of states have recently been considering legislation around interchangeable biosimilar substitution at the pharmacy level. Vermont and Connecticut are among the 2 latest states to enact such regulation.
On May 30, 2018, Vermont Governor Phil Scott signed bill S.92 into law as Act No. 193. The Act instructs pharmacists to dispense the lowest-price interchangeable biological product to the patient, as well as notify the prescriber of which biological product has been dispensed.
Specifically, within 5 days of the biological product being dispensed, the pharmacist must communicate to the prescriber electronically through either an interoperable electronic medical records system, an electronic prescribing technology, a pharmacy benefit management system, or a pharmacy record.
In Connecticut, Governor Dannel Malloy signed S. Bill No. 197 into law as Public Act No. 18-74 on June 4, 2018. The Act allows a pharmacist to substitute an interchangeable biological product for a prescribed biological product if it provides a cost saving to the patient. In addition, the Act also includes provisions stipulating the notification to the patient purchasing the drug that there may be a cheaper interchangeable biological product available.
The Act also requires the dispensing physician to make an entry documenting the substitution, as well as inform the prescribing practitioner by facsimile, telephone, or electronic transmission of the substitution.
With the implementation of these laws, Vermont and Connecticut have joined 43 other states and Puerto Rico that have authorized legislation around the substitution of interchangeable biosimilars, despite the FDA having not approved such a product to date.
New Hampshire and Alaska are currently considering similar legislation.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
